Table 2.

Univariate and multivariate risk factor analysis for invasive aspergillosis

Variable	Invasive aspergillosis
	Univariate analysis		Multivariate analysis
	4 year Cum. Inc.	P-value	HR (95%CI)	P-value
Patient age
<55 years	13
>55 years	14	0.9	NA
Patient sex
Male	15
Female	11	0.6	NA
Diagnosis
AL and MDS	11
Others	15	0.7	NA
Advanced disease
Yes	15
No	10	0.4	NA
Conditioning regimen
Fludarabine–Melphalan	14
Fludarabine–BU	12	0.3	NA
Donor type
HLA-id sibling	10
Alternative donors	24	0.01	NA	0.5
Acute GVHD prophylaxis
CsA–MMF	23
CsA–MTX	9	0.01	NA	0.2
Alemtuzumab/ATG
Yes	21
No	9	0.03	NA	0.15
Monocytopenia a , b
Yes	22
No	7	0.02	NA	0.2
Acute GVHD II-IV a
Yes	18
No	8	0.01	NT
Steroid therapy for msGVHD c , a
Yes (n=106)	22
No	6	<0.01	2.9 (1.1–7.6)	0.03
CMV infection w/o disease a
Yes	15
No	12	0.4	NA
CMV disease a
Yes (n=25)	38
No	9	<0.01	2.8 (1.1–6.8)	0.03
RTI by a respiratory virus a
No	7
URTI only	9
LRTI (n=27)	33	<0.01d	4.3 (2–9.4)d	<0.01d

Abbreviations: ATG=antithymocyte globulin; AL=acute leukemia; Cum. Inc.=cumulative incidence; CI=confidence interval; GVHD=graft-vs-host disease; HR=hazard ratio; LRTI=lower RTI; MDS=myelodysplastic syndrome; MMF=mycophenolate mofetil; msGVHD=moderate-to-severe graft-vs-host disease; RTI=respiratory tract infection; URTI=upper RTI.

^aThese variables were analyzed as time-dependent covariates.

^bMonocytopenia (< 0.1 × 10⁹/l), considered as a time-dependent covariate, was analyzed according to the monocyte count at the start of each of the following time periods: days+28–+100, days +101–+365 and day +366 onwards.

^cDefined as a dose of prednisone of 2 mg/kg/day or equivalent for a total of at least 14 days.

^dRefers to the comparison of LRTI with the combination of no CRV infection and URTI only.